![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/d/d4/Estradiol_pivalate_structure.svg/640px-Estradiol_pivalate_structure.svg.png&w=640&q=50)
Estradiol pivalate/progesterone
Combination drug / From Wikipedia, the free encyclopedia
Estradiol pivalate/progesterone (ETMA/P4), sold under the brand name Estrotate with Progesterone, is a combination medication of estradiol pivalate (estradiol trimethylacetate; ETMA), an estrogen, and progesterone (P4), a progestogen, which was used in menopausal hormone therapy and the treatment of gynecological disorders but is no longer available.[1][2][3] It contained 1 mg/mL ETMA and 10 mg/mL P4 in oil solution provided in vials and was administered by intramuscular injection at regular intervals.[1][2][3]
![]() | |
![]() | |
Combination of | |
---|---|
Estradiol pivalate | Estrogen |
Progesterone | Progestogen |
Clinical data | |
Trade names | Estrotate with Progesterone |
Other names | ETMA/P4; EP/P4 |
Routes of administration | Intramuscular injection |
ETMA/P4 was introduced for medical use by 1949.[1][2][3] It was one of the first combined estrogen and progestogen medications to be marketed, and was followed by the more well-known estradiol benzoate/progesterone (brand name Duogynon) in 1950.[4] Other similar estrogen–progestogen preparations were also subsequently introduced.[4]